Your Health, We Care
Release date: 2026-05-06 13:34:03 Article From: Lucius Laos Recommended: 11
Do not take Finerenone if you are allergic to Finerenone or any of its other ingredients. You are also prohibited from taking Finerenone if you are taking any medicines that are "strong CYP3A4 inhibitors" (for example, itraconazole or ketoconazole for fungal infections; ritonavir, nelfinavir, or cobicistat for HIV infection; clarithromycin, telithromycin for bacterial infections; and nefazodone for depression). In addition, you must not use this medicine if you have Addison's disease (a condition where the body cannot produce enough cortisol and aldosterone).
Before taking Finerenone, please inform your doctor specifically if: you have been told by a doctor that you have high potassium levels in your blood; you have severe loss of kidney function or kidney failure; you have moderate or severe liver problems; or you have mild, moderate, or severe heart failure (where the heart cannot pump blood effectively and outputs insufficient blood with each beat). These conditions may affect the safety of this medicine, and your doctor will need to assess your specific situation to determine whether the medicine is suitable for you.
Blood tests are required during treatment to monitor your potassium levels and kidney function. Based on the blood test results, your doctor will decide whether you can start taking Finerenone. Four weeks after starting the medicine, you will need to have another blood test. Your doctor may also schedule additional tests at other times (for example, when you are taking other medicines). Use in children and adolescents: This medicine must not be used in individuals under 18 years of age, because the safety and efficacy of its use in this age group have not been established.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3002025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5172024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3002025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3142025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2882025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3412025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2922025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2702025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
